Previous close | 61.09 |
Open | 61.00 |
Bid | 61.46 x 1400 |
Ask | 61.46 x 1000 |
Day's range | 60.82 - 61.61 |
52-week range | 57.17 - 74.12 |
Volume | |
Avg. volume | 7,223,551 |
Market cap | 77.178B |
Beta (5Y monthly) | 0.35 |
PE ratio (TTM) | 18.82 |
EPS (TTM) | 3.27 |
Earnings date | 26 Oct 2022 - 31 Oct 2022 |
Forward dividend & yield | 2.92 (4.78%) |
Ex-dividend date | 14 Sept 2022 |
1y target est | 69.96 |
Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.
FOSTER CITY, Calif. & OXFORD, England, August 04, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.